#AS­CO17: In­cyte gets a boost from a se­ries of pos­i­tive da­ta snap­shots for its epaca­do­stat/Keytru­da com­bo

Wednes­day evening brought with it the da­ta dump on ab­stracts for the up­com­ing an­nu­al AS­CO con­fab in Chica­go in ear­ly June, and the big pre­lim­i­nary win­ner — not a big sur­prise — was In­cyte, with a slate of new da­ta points un­der­scor­ing the po­ten­tial of its lead­ing, late-stage IDO1 drug epaca­do­stat in com­bi­na­tion with Mer­ck’s Keytru­da.

In­cyte shares $IN­CY swelled 9.5% in af­ter-mar­ket trad­ing as in­vestors got a glimpse of things to come, with a 30%-plus re­sponse rate for a full slate of com­bi­na­tion stud­ies that are now push­ing in­to Phase III de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER